

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05374 A1

- (51) International Patent Classification⁷: A61K 9/127
- (21) International Application Number: PCT/CA00/00843
- (22) International Filing Date: 14 July 2000 (14.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/143,978 15 July 1999 (15.07.1999) US
- (71) Applicant (for all designated States except US): INEX PHARMACEUTICALS CORP. [CA/CA]; 100 - 8900 Glen Lyon Parkway, Burnaby, British Columbia V5J 5J8 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MAURER, Norbert [AT/CA]; 2252 Allison Road, Vancouver, British Columbia V6T 1T6 (CA). WONG, Kim, F. [CA/CA]; 4595 West 13th Avenue, Vancouver, British Columbia V6R 2V5 (CA). CULLIS, Pieter, R. [CA/CA]; 3732 West 1st Avenue, Vancouver, British Columbia V6R 1H4 (CA).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
- With international search report.
 - Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS



(57) Abstract: Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.

100221 55161001

WO 01/05374 A1